CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 15 enrolled
Drug / intervention
Rituximab +1 moredrug
Likely dose
Rituximab 375 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04585893
NCT04585893Phase 2Active
CompareCT.gov

LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy Trial

UNC Lineberger Comprehensive Cancer Center·interventional·Posted Oct 14, 2020·Updated Sep 11, 2025

In Brief

A Phase 2 clinical trial evaluating Rituximab and Etoposide for Multicentric Castleman Disease. Active but no longer recruiting, targeting 15 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial. This study also aims to compare the cost-effectiveness of first-line Rituximab treatment for MCD in Malawi to chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMulticentric Castleman Disease
CountriesMalawi
CollaboratorsFogarty International Center of the National Institute of Health

Timeline

Phase 2ActiveOverdue
202120222023202420252026
First PostedOct 14, 2020
Enrollment StartJun 22, 2021
Primary CompletionAug 30, 2024
Study CompletionJun 7, 2026
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.7 years ago

Interventions

Rituximabdrug

375 mg/m\^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.

Etoposidedrug

Subjects with high-risk disease will receive 100 mg/m\^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab